医学
常染色体显性多囊肾病
肾细胞癌
肾
肾脏疾病
泌尿科
多囊肾病
肾病科
人口
透析
肾癌
内科学
病理
环境卫生
作者
Cordula A. Jilg,Vanessa Drendel,Janina Bacher,Przemyslaw Pisarski,Hannes Neeff,Oliver Drognitz,M. Schwardt,Sven Gläsker,Angelica Malinoc,Zoran Erlic,Mercedes Núñez,A. Wéber,Pablo Javier Azurmendi,Wolfgang Schultze‐Seemann,Martin Werner,Hartmut P.H. Neumann
出处
期刊:Nephron
[S. Karger AG]
日期:2013-06-04
卷期号:123 (1-2): 13-21
被引量:60
摘要
<b><i>Background:</i></b> The role of autosomal dominant polycystic kidney disease (ADPKD) as a risk factor for renal cell carcinoma (RCC) is still under discussion. Data on prevalence of RCC in ADPKD are limited, especially on a large population scale. The aim of this study was to analyze the prevalence of RCC in ADPKD kidneys and characterize the clinical features of this coincidence. <b><i>Methods:</i></b> Based on our histopathological registry for ADPKD and the Else Kröner-Fresenius Registry, we retrospectively reviewed malignant and benign renal lesions in patients with ADPKD who had undergone renal surgery from 1988 to 2011. <b><i>Results:</i></b> 240 ADPKD patients underwent 301 renal surgeries. Mean age at surgery was 54 years. Overall, 16 malignant and 11 benign lesions were analyzed in 301 kidneys (5.3%; 3.7%), meaning that 12/240 (5%; 1:20) patients presented with malignant renal lesions. 66.7% (8/12) of these patients had undergone dialysis prior to surgery. We found 10/16 (63%) papillary RCC, 5/16 (31%) clear cell RCC, and 1/16 (6%) papillary noninvasive urothelial cancer. Regarding all renal lesions, 6/17 (35.3%) patients had more than one histological finding in their kidneys. In 2 cases, metachronous metastases were removed. Mean follow-up was 66.7 months. <b><i>Conclusion:</i></b> Kidney-related prevalence of RCC in ADPKD kidneys was surprisingly high. Whether or not this is due to chronic dialysis or due to the underlying disease is still speculative. Like other cystic renal diseases with an increased risk for RCC, the attending physician should be aware of the malignant potential of ADPKD, especially with concomitant dialysis.
科研通智能强力驱动
Strongly Powered by AbleSci AI